| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-91091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-452
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4406
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4409
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4406
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4409
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2010-07-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2012-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2012533530-A |
| titleOfInvention |
A method for predicting the efficacy of nicotinic acid or its precursor or prodrug administration to reduce the severity of side effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors |
| abstract |
The present application is a method for treating or alleviating symptoms of cancer in a subject comprising: a) determining the level of nicotinic acid phosphoribosyltransferase (NAPRT) in said subject; and b) the NAPRT level is below a predetermined threshold Or i) treating said subject sequentially / simultaneously with an effective amount of a nicotinamide phosphoribosyltransferase inhibitor (NAMPRTi) and ii) an effective amount of nicotinic acid, a nicotinic acid precursor or a prodrug of nicotinic acid; or 2) if the NAPRT level is above a predetermined threshold, ii) in the absence of continuous / co-treatment with an effective amount of nicotinic acid, nicotinic acid precursor or prodrug of nicotinic acid, i) said effective amount of NAMPRTi Disclosed are methods comprising treating a subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020517599-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20180010138-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101941054-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019530697-A |
| priorityDate |
2009-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |